Exploratory Phase II Study of KRP-203 -A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of KRP-203 in Patients with Crohn's Disease in Active Phase-

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222062

Enrollment

Registered

2013-04-18

Start date

2013-04-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Interventions

investigational material(s) Generic name etc : KRP-203 INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients who were diagnosed with Crohn's disease according to diagnostic criteria, etc.

Exclusion criteria

Exclusion criteria: -Patients with a colostomy or ileostomy. -Patients with a short gut syndrome or imflammatory bowel disease except Crohn's disease, etc.

Design outcomes

Primary

Measure	Time frame
CDAI The improvement of CDAI.	—

Secondary

Measure	Time frame
Inflammation markers,etc. CRP, etc.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026